This article was originally published in The Tan Sheet
Aventis' Allegra, Schering-Plough's Clarinex, Pfizer's Zyrtec likely will "be moved to a higher tier of co-payment in terms of...managed care formularies" with out-of-pocket costs "being in the range of $25 to $30" when Schering's Claritin switches OTC, Aventis Investor Relations Director Arvind Sood predicts during Q2 analysts call July 31. However, with a monthly supply of Claritin expected to cost about the same, the likelihood that Allegra customers will switch to Claritin "is going to be minimal," Sood maintains...
You may also be interested in...
Unilever’s Suave brand led new sanitizer product sales in 2020, when hand sanitizers total sales grew 569%, according to IRI. Sales of rinseable hand-soap sales grew 64% and antiseptics 19%.
The pandemic has exacerbated the problems of the Turkish medical device industry, which was already struggling for survival and growth in a hostile policy environment. Local blood bag manufacturer Kansuk Laboratory talked to Medtech Insight about the difficulties it faces.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.